Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Urology›Condition·Updated Jul 11, 2026·v1

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia is a progressive condition in aging men, managed with a stepwise approach from watchful living to medical therapy (α-blockers, 5-ARIs, tadalafil) to minimally invasive and surgical options based on symptom severity, prostate volume, and patient preference. Key thresholds include IPSS ≥8 for treatment initiation, prostate volume ≥30 mL for 5-ARI benefit, and Qmax <10 mL/s for obstruction.

High Evidence371 references·10,622 words·43 min read·v1
urologyBPHLUTSlower urinary tract symptomsprostatealpha-blocker5-alpha-reductase inhibitorTURPHoLEPMISTbenign prostatic hyperplasia

Quick Reference

RxDrug of choiceTamsulosin 0.4 mg daily (α-blocker) for moderate LUTS; add dutasteride 0.5 mg daily (5-ARI) if prostate volume ≥30 mL or PSA ≥1.5 ng/mL.
AltAlternativesTadalafil 5 mg daily (for men with concurrent ED), vibegron 75 mg daily (for persistent OAB symptoms), or fixed-dose dutasteride/tadalafil 0.5/5 mg daily.
⊘AvoidSaw palmetto, intraprostatic botulinum toxin A, non-dihydropyridine CCBs (diltiazem, verapamil) - exacerbate LUTS.
DxTest of choiceIPSS (symptom severity), uroflowmetry with PVR (obstruction assessment), and transrectal ultrasound (prostate volume).
ScKey scoreIPSS (0-35) for symptom severity; Bladder Outlet Obstruction Index (BOOI) ≥40 for urodynamic obstruction.
→When to referFailed medical therapy (IPSS <3-point improvement or persistent dissatisfaction), acute urinary retention, prostate >80 mL, hematuria, bladder stones, recurrent UTIs, renal impairment due to obstruction, or desire for definitive treatment.
Medical therapy with α-blockers and 5-ARIs reduces symptoms and progression risk; MISTs and surgery are reserved for refractory cases, with choice guided by prostate size, sexual function priorities, and comorbidity status.
Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms (LUTS) in aging men, with histologic prevalence exceeding 50% by age 60 and 90% by age 85. Management is driven by symptom severity, prostate volume, and patient preference for preserving sexual function. First-line medical therapy includes α-blockers for moderate symptoms; 5α-reductase inhibitors (5-ARIs) reduce progression risk in men with enlarged prostates. For those who fail medical therapy or desire definitive treatment, minimally invasive surgical therapies (MISTs) and surgical options (TURP, HoLEP, Aquablation) offer durable symptom relief with varying risks and benefits. This page provides a comprehensive overview of diagnosis, medical and surgical management, and special population considerations.

Overview and Recommendations

Background

  • •Benign prostatic hyperplasia is a histologic diagnosis defined by non‑malignant proliferation of stromal and epithelial cells in the prostate transition zone, leading to gland enlargement that may cause bladder outlet obstruction and lower urinary tract symptoms (LUTS). The term is distinct from the clinical syndrome of LUTS and the urodynamic entity of benign prostatic obstruction (BPO).
  • •BPH is among the most common conditions in aging men: histologic prevalence increases from ~50% at age 60 to >90% by age 85. In the U.S., approximately 6.7 million men are affected, and the condition accounts for a large proportion of primary care visits and urologic surgeries.
  • •Pathophysiology involves two parallel components: a static component driven by androgen-dependent (dihydrotestosterone) and inflammation-mediated cellular hyperplasia, and a dynamic component mediated by α1-adrenergic receptor activation on prostatic smooth muscle, causing reversible urethral resistance. Chronic inflammation and oxidative stress (including ferroptosis) are increasingly recognized contributors.
  • •Prognosis is progressive in most men. The Olmsted County study documented an annual IPSS increase of 0.18 points, 2% decline in peak flow, and 1.9% increase in prostate volume per year. The cumulative incidence of acute urinary retention (AUR) over 4 years is 2.7%, and the 5-year risk of progression (≥4-point IPSS increase, AUR, or surgery) is 15-20% in men with moderate symptoms.
  • •Prostate volume (by TRUS) and serum PSA (≥1.5 ng/mL) are the best surrogate markers of progression risk. The Slawin nomogram incorporating AUA-SI, BPH Impact Index, prior α-blocker use, prostate volume, PSA, and Qmax predicts 2-year risk of AUR/surgery with a concordance index of 0.71, identifying high-risk men (maximal predicted risk 27% vs. median 7.4% on placebo).

Evaluation

  • •Suspect BPH in any man >40 years presenting with storage symptoms (frequency, urgency, nocturia) or voiding symptoms (hesitancy, weak stream, intermittency, straining). Administer the International Prostate Symptom Score (IPSS) to quantify severity: mild (0-7), moderate (8-19), severe (20-35).
  • •Perform a digital rectal examination (DRE) to assess prostate size, consistency, and symmetry. A BPH-affected prostate is symmetrically enlarged, smooth, firm, and elastic; nodules or asymmetry raise suspicion for and require further evaluation.
  • •Order urinalysis to exclude urinary tract infection or hematuria, and check serum creatinine to screen for renal impairment from chronic obstruction. Measure serum PSA to estimate prostate volume and assess cancer risk; a PSA <1.5 ng/mL with a smooth DRE makes cancer unlikely.
  • •Obtain uroflowmetry and post-void residual (PVR) measurement. A maximum flow rate (Qmax) <10 mL/s on a voided volume ≥150 mL suggests bladder outlet obstruction; PVR >100 mL indicates incomplete emptying, and >200 mL raises concern for detrusor decompensation.
  • •If the diagnosis remains uncertain or surgery is planned, obtain transrectal ultrasound (TRUS) to measure total prostate volume and transitional zone volume. Intravesical prostatic protrusion (IPP) correlates with obstruction severity.
  • •For equivocal cases or prior failed therapy, consider pressure-flow urodynamics. The Bladder Outlet Obstruction Index (BOOI = pdetQmax - 2Qmax) ≥40 defines obstruction; BOOI 20-40 is equivocal. Urodynamics also identifies detrusor underactivity, which predicts poorer surgical outcomes (pooled mean difference in IPSS improvement -3.73).
  • •Reserve cystoscopy for patients with hematuria, suspected urethral stricture, or prior to minimally invasive surgical therapy (MIST) to assess anatomy. Bladder trabeculation grade on cystoscopy correlates with BOO severity (AUC 0.72).
  • •In men with moderate-to-severe LUTS, assess risk factors for progression: age >70, prostate volume >30 mL, PSA >1.5 ng/mL, Qmax <10, and PVR >100. Use the Slawin nomogram to quantify 2-year risk of AUR/surgery.
  • •Differentiate BPH from other causes of LUTS: overactive bladder (OAB) in the absence of obstruction, prostatitis, neurogenic bladder (especially in patients with Parkinson's, multiple sclerosis, or spinal cord injury), and nocturnal polyuria (use a voiding diary).
  • •In patients with acute urinary retention (AUR), confirm by history and suprapubic palpation, perform immediate bladder drainage (urethral or suprapubic catheter), and start α-blocker therapy. Document drained volume; >1000 mL indicates chronic retention and carries risk of post-obstructive diuresis.

Management

  • •For mild LUTS (IPSS 0-7, not bothersome), initiate watchful waiting with lifestyle modifications: reduce fluid intake before bedtime, avoid caffeine and alcohol, schedule voiding, and manage constipation.
  • •For moderate-to-severe LUTS (IPSS ≥8), start an α1-blocker as first-line therapy: tamsulosin 0.4 mg once daily, alfuzosin 10 mg once daily, or silodosin 8 mg once daily. Monitor for orthostatic hypotension, dizziness, and retrograde ejaculation (up to 70% with tamsulosin).
  • •In men with prostate volume ≥30 mL or PSA ≥1.5 ng/mL, add a 5α-reductase inhibitor (5-ARI) to reduce progression risk: finasteride 5 mg daily or dutasteride 0.5 mg daily. Combination therapy (α-blocker + 5-ARI) reduces the risk of AUR or surgery by ~50% compared to α-blocker alone (NNT = 27 over 2 years).
  • •For men with LUTS and erectile dysfunction, offer tadalafil 5 mg once daily as an alternative to α-blockers. Tadalafil improves IPSS by 3-4 points and Qmax by 2-3 mL/s, with additional benefit of sexual function.
  • •For persistent storage symptoms despite α-blocker therapy, consider add-on vibegron 75 mg daily (β3-agonist) or low-dose antimuscarinics (e.g., solifenacin 5 mg). Monitor for urinary retention, especially in men with PVR >150 mL. Avoid non-dihydropyridine CCBs like diltiazem and verapamil.
  • •Avoid saw palmetto (no benefit over placebo), intraprostatic botulinum toxin A (no proven efficacy), and chronic anti-inflammatory therapy for BPH.
  • •After 4-12 weeks of medical therapy, reassess IPSS and patient satisfaction. If improvement is <3 points or dissatisfaction persists, consider switching α-blocker, adding 5-ARI, or proceeding to procedural intervention.
  • •For men who desire definitive treatment or have failed medical therapy, discuss minimally invasive surgical therapies (MISTs) for moderate-to-severe LUTS with prostate volume 30-80 mL: water vapor thermal therapy (Rezūm) provides 48% IPSS reduction at 5 years with 4.4% retreatment rate and preserved sexual function. Prostatic urethral lift (UroLift) preserves ejaculation and is preferred for men without a large middle lobe.
  • •Prostatic artery embolization (PAE) is a MIST option for men with prostate volume 80-250 mL; it produces similar IPSS improvement to HoLEP at 1 year with better sexual function preservation, though Qmax improvement is less robust.
  • •Surgical desobstruction is indicated for severe symptoms, prostate >80 mL, refractory retention, or renal impairment. Transurethral resection of the prostate (TURP) is the historical gold standard: IPSS improvement 77%, Qmax increase 119%, retrograde ejaculation 72%. Modern bipolar TURP has ≤0.4% transfusion rate and 0% TUR syndrome. Holmium laser enucleation (HoLEP) is size-independent with lower transfusion risk and shorter catheterization.
  • •For acute urinary retention (AUR), perform immediate catheterization, start α-blocker, and schedule a trial without catheter (TWOC) after 3-5 days. TWOC success is approximately 60% with α-blocker; failure requires definitive surgery. For patients on anticoagulation, use photoselective vaporization (PVP) or HoLEP to minimize bleeding risk.
  • •After surgical treatment, obtain a new PSA nadir at 3-6 months to enable accurate prostate cancer surveillance. Enucleation procedures produce the largest PSA drop; MISTs produce smaller reductions. Refer to urology for failed medical therapy, recurrent AUR, hematuria, bladder stones, recurrent UTIs, or renal impairment due to obstruction.

Board Review — High Yield

  • •IPSS - Score 0-35; mild (0-7), moderate (8-19), severe (20-35); minimal clinically important difference is 4 points.
  • •Qmax <10 mL/s - Suggests bladder outlet obstruction; repeat at least twice for consistency.
  • •BOOI ≥40 - Urodynamic gold standard for obstruction; BOOI = pdetQmax - 2Qmax.
  • •5-ARIs reduce PSA by 50% - PSA nadir at 6 months; used to estimate prostate volume and monitor progression.
  • •Combination therapy (α-blocker + 5-ARI) - Reduces risk of AUR/surgery by 50% vs α-blocker alone (NNT=27 over 2 years).
  • •TURP - Gold standard surgery; IPSS improvement 77%, retrograde ejaculation 72%, transfusion rate 0.4% with bipolar.
  • •HoLEP - Size-independent; lower transfusion risk, catheterization ~1.3 days; preserves ejaculation no better than standard TURP.
  • •Rezūm (water vapor therapy) - MIST with 48% IPSS reduction at 5 years, 4.4% retreatment rate, no negative impact on sexual function.
  • •PSA nadir after surgery - Obtain at 3-6 months; enucleation gives largest drop, MISTs smaller.
  • •Slawin nomogram - Predicts 2-year risk of AUR/surgery (concordance 0.71); incorporates AUA-SI, BPH Impact Index, α-blocker use, volume, PSA, Qmax.

Deep Dive — Evidence Details

References

  1. [1]

    Johnson AR, Munoz A, Gottlieb JL et al.. “High dose zinc increases hospital admissions due to genitourinary complications.” The Journal of urology (2007). PMID: 17222649 ↗

    L2RCTCited in: Definition, Classification & Nomenclature
  2. [2]

    Galosi AB, Montironi R, Fabiani A et al.. “Cystic lesions of the prostate gland: an ultrasound classification with pathological correlation.” The Journal of urology (2008). PMID: 19091354 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  3. [3]

    Vaughan CP, Johnson TM, Haukka J et al.. “The fluctuation of nocturia in men with lower urinary tract symptoms allocated to placebo during a 12-month randomized, controlled trial.” The Journal of urology (2013). PMID: 24333108 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  4. [4]

    Clemens JQ, Meenan RT, O'Keeffe Rosetti MC et al.. “Prevalence of and risk factors for prostatitis: population based assessment using physician assigned diagnoses.” The Journal of urology (2007). PMID: 17706722 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature
  5. [5]

    Feiertag N, Tawfik MM, Loloi J et al.. “Should Men Eat More Plants? A Systematic Review of the Literature on the Effect of Plant-Forward Diets on Men's Health.” Urology (2023). PMID: 36963667 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  6. [6]

    Song L, Zhu Y, Han P et al.. “A retrospective study: correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen.” Urology (2010). PMID: 20974483 ↗

    L4COHORTCited in: Definition, Classification & Nomenclature
  7. [7]

    Clennon EK, Martinez Acevedo A, Sajadi KP. “Safety and effectiveness of zero antimicrobial prophylaxis protocol for outpatient cystourethroscopy.” BJU international (2019). PMID: 30578737 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  8. [8]

    Volpe A, Billia M, Quaglia M et al.. “Transurethral resection of the prostate in kidney transplant recipients: urological and renal functional outcomes at long-term follow-up.” BJU international (2013). PMID: 23496755 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  9. [9]

    Barry MJ, Link CL, McNaughton-Collins MF et al.. “Overlap of different urological symptom complexes in a racially and ethnically diverse, community-based population of men and women.” BJU international (2007). PMID: 17868419 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  10. [10]

    Lotfy AM, Kamel MM, Abdallah M et al.. “Safety and Efficacy of Bipolar Transurethral Vaporization of the Prostate and Bipolar Transurethral Resection of the Prostate in the Management of Large Volume Benign Prostatic Hyperplasia: A Prospective Randomized Study.” The Prostate (2026). PMID: 42018529 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Complications, Prognosis & Natural History
  11. [11]

    Kang TW, Jung JH, Hwang EC et al.. “Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2020). PMID: 32212174 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Acute Management & Decompression, Complications
  12. [12]

    Bouhadana D, Lu XH, Luo JW et al.. “Clinical Applications of Machine Learning for Urolithiasis and Benign Prostatic Hyperplasia: A Systematic Review.” Journal of endourology (2022). PMID: 36266993 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  13. [13]

    Hashim H, Tarcan T, Acar O et al.. “Evaluation of new treatments for benign prostatic obstruction: ICI-RS 2023.” Neurourology and urodynamics (2023). PMID: 38078704 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompression, History and Evolution of Treatment, Prognosis & Natural History
  14. [14]

    Xu P, Patel A, Roane A et al.. “The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis.” World journal of urology (2026). PMID: 42258011 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  15. [15]

    Oelke M, Adler E, Marschall-Kehrel D et al.. “Nocturia: state of the art and critical analysis of current assessment and treatment strategies.” World journal of urology (2014). PMID: 25216925 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature
  16. [16]

    Porto JG, Arbelaez MCS, Blachman-Braun R et al.. “Complications associated with minimally invasive surgical therapies (MIST) for surgical management of benign prostatic hyperplasia: a Manufacturer and User Facility Device Experience (MAUDE) database review.” World journal of urology (2023). PMID: 37222779 ↗

    L4REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  17. [17]

    Lekili M, Müezzinoğlu T, Uyanik BS et al.. “Serum lipid levels in benign prostatic hyperplasia.” World journal of urology (2006). PMID: 16506048 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  18. [18]

    Mamoulakis C, Efthimiou I, Kazoulis S et al.. “The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate.” World journal of urology (2010). PMID: 20461386 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  19. [19]

    . “Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.” Singapore medical journal (2017). PMID: 28848988 ↗

    L1GUIDELINECited in: Definition, Classification & Nomenclature
  20. [20]

    Goueli R, Badlani GH, Welliver C et al.. “Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part I: Presentation and Evaluation.” The Journal of urology (2026). PMID: 42095481 ↗

    L1GUIDELINECited in: Pathophysiology & Mechanism, Clinical Presentation, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
  21. [21]

    Goueli R, Badlani GH, Welliver C et al.. “Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.” The Journal of urology (2026). PMID: 42095477 ↗

    L1GUIDELINECited in: Pathophysiology & Mechanism, Clinical Presentation, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prevention, Screening & Surveillance
  22. [22]

    Goueli R, Badlani GH, Welliver C et al.. “Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part III: Procedural/Surgical Management.” The Journal of urology (2026). PMID: 42095468 ↗

    L1GUIDELINECited in: Pathophysiology & Mechanism, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
  23. [23]

    Abrams P, Chapple C, Khoury S et al.. “Evaluation and treatment of lower urinary tract symptoms in older men.” The Journal of urology (2009). PMID: 19233402 ↗

    L1GUIDELINECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Complications
  24. [24]

    Light A, Jabarkhyl D, Gilling P et al.. “Erectile Function Following Surgery for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials.” European urology (2021). PMID: 34127315 ↗

    L1SR_MA_RCTCited in: Pathophysiology & Mechanism, Endoscopic & Procedural Technique Considerations
  25. [25]

    Gilling P, Anderson P, Tan A. “Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: 1-Year Results.” The Journal of urology (2017). PMID: 28111300 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Endoscopic & Procedural Technique Considerations
  26. [26]

    Cornu JN, Zantek P, Burtt G et al.. “Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis.” European urology (2023). PMID: 36964042 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
  27. [27]

    Rassweiler J, Teber D, Kuntz R et al.. “Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention.” European urology (2006). PMID: 16469429 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management & Decompression, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Complications, Prognosis & Natural History
  28. [28]

    Creta M, Russo GI, Bhojani N et al.. “Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review.” European urology (2024). PMID: 38749852 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
  29. [29]

    Fusco F, Palmieri A, Ficarra V et al.. “α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.” European urology (2016). PMID: 26831507 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup
  30. [30]

    Franco A, Ditonno F, Manfredi C et al.. “Systematic Review and Pooled Analysis of Functional and Sexual Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Obstruction.” European urology (2025). PMID: 40967932 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism
  31. [31]

    Kim M, Jeong CW, Oh SJ. “Effect of Preoperative Urodynamic Detrusor Underactivity on Transurethral Surgery for Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.” The Journal of urology (2017). PMID: 28760632 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup
  32. [32]

    Brown N, Kiosoglous A, Castree S et al.. “The 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH.” BJU international (2024). PMID: 39139009 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  33. [33]

    Viitala A, Anttinen M, Mäkelä P et al.. “Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study.” BJU international (2025). PMID: 40432395 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism, Complications
  34. [34]

    Costa Silva A, Pina-Vaz T, Morgado A et al.. “Prevalence of non-neurogenic male lower urinary tract symptoms after kidney transplantation.” BJU international (2024). PMID: 38520403 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation
  35. [35]

    Hashmi TM, Zia R, Ashraf H et al.. “Tamsulosin plus Tadalafil compared with Tamsulosin alone for benign prostate hyperplasia in patients with or without erectile dysfunction: a meta-analysis and meta-regression of randomized controlled trials.” World journal of urology (2025). PMID: 40349279 ↗

    L1SR_MA_RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
  36. [36]

    Rovner ES, Owens-Grillo J, Thomas E et al.. “Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.” Neurourology and urodynamics (2025). PMID: 41363221 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  37. [37]

    Lebdai S, Delongchamps NB, Sapoval M et al.. “Early results and complications of prostatic arterial embolization for benign prostatic hyperplasia.” World journal of urology (2015). PMID: 26276151 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Acute Management & Decompression, Prognosis & Natural History
  38. [38]

    Yilmaz M, Karaaslan M, Polat ME et al.. “Is day-case surgery feasible for laser endoscopic enucleation of the prostate? A systematic review.” World journal of urology (2023). PMID: 37689604 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism, Complications
  39. [39]

    Zhong J, Feng Z, Peng Y et al.. “A Systematic Review and Meta-analysis of Efficacy and Safety Following Holmium Laser Enucleation of Prostate and Transurethral Resection of Prostate for Benign Prostatic Hyperplasia.” Urology (2019). PMID: 31129190 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism
  40. [40]

    Hao N, Tian Y, Liu W et al.. “Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms--a meta-analysis.” Urology (2013). PMID: 24361007 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Acute Management & Decompression
  41. [41]

    Devlin CM, Simms MS, Maitland NJ. “Benign prostatic hyperplasia - what do we know?” BJU international (2020). PMID: 32893964 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  42. [42]

    Ilie CP, Mischianu DL, Pemberton RJ. “Painful ejaculation.” BJU international (2007). PMID: 17346279 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical
  43. [43]

    Jain A, Nassour AJ, Khannani H et al.. “Australian surgical revision rate for benign prostatic obstruction.” BJU international (2023). PMID: 37346012 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Endoscopic & Procedural Technique Considerations
  44. [44]

    Lv Z, Wang Y, Lv C et al.. “Global stagnation and misaligned priorities in BPH drug development: a 25-year landscape analysis of clinical trial registries.” npj aging (2026). PMID: 42000718 ↗

    L2TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism
  45. [45]

    Liu H, Wang X, Shi X. “Transurethral anatomical enucleation of the prostate using a 1470-nm diode laser (DiLEP) versus transurethral resection of the prostate (TURP) for large-volume benign prostatic hyperplasia: a prospective randomized controlled trial.” Lasers in medical science (2026). PMID: 42149256 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Endoscopic & Procedural Technique Considerations, Complications, Prognosis & Natural History
  46. [46]

    Hoffman RM, Monga M, Elliot SP et al.. “Microwave thermotherapy for benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2007). PMID: 17943811 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  47. [47]

    Hoffman RM, Monga M, Elliott SP et al.. “Microwave thermotherapy for benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2012). PMID: 22972068 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  48. [48]

    Wilt TJ, Howe RW, Rutks I et al.. “WITHDRAWN: Terazosin for benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2011). PMID: 21901686 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, History and Evolution of Treatment
  49. [49]

    Silva LA, Andriolo RB, Atallah ÁN et al.. “Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery.” The Cochrane database of systematic reviews (2014). PMID: 25261861 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Complications
  50. [50]

    Andersson KE. “LUTS treatment: future treatment options.” Neurourology and urodynamics (2007). PMID: 17696154 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
  51. [51]

    Shapiro KK, Brucker BM. “Treatment of overactive bladder in men: Is it really different?” Neurourology and urodynamics (2022). PMID: 35781322 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
  52. [52]

    Hennenberg M, Stief CG, Gratzke C. “Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling.” Neurourology and urodynamics (2013). PMID: 24038148 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  53. [53]

    Oelke M, Kirschner-Hermanns R, Thiruchelvam N et al.. “Can we identify men who will have complications from benign prostatic obstruction (BPO)? ICI-RS 2011.” Neurourology and urodynamics (2012). PMID: 22415947 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management & Decompression, Special Populations & Pregnancy
  54. [54]

    Foo KT. “What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?” World journal of urology (2019). PMID: 30805683 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification
  55. [55]

    Peyronnet B, Brucker BM, De Nunzio C et al.. “Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.” World journal of urology (2025). PMID: 40856729 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  56. [56]

    Yang D, Zhai C, Ren J et al.. “Hydroxycitric acid inhibits ferroptosis and ameliorates benign prostatic hyperplasia by upregulating the Nrf2/GPX4 pathway.” World journal of urology (2025). PMID: 40392347 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  57. [57]

    Paniagua Cruz A, Zhu KY, Ellimoottil C et al.. “Characterizing the Benign Prostatic Hyperplasia Literature: A Bibliometric Analysis.” Urology (2019). PMID: 31801683 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
  58. [58]

    Weiss JP, Everaert K. “Management of Nocturia and Nocturnal Polyuria.” Urology (2019). PMID: 31586470 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  59. [59]

    Wu Y, Lv K, Zhao Y et al.. “Prediction Model for Detrusor Underactivity via Noninvasive Clinical Parameters in Men With Benign Prostatic Hyperplasia.” Urology (2025). PMID: 40683565 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  60. [60]

    Chermansky CJ, Chancellor MB. “Use of Botulinum Toxin in Urologic Diseases.” Urology (2016). PMID: 26777748 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  61. [61]

    Lerner LB, McVary KT, Barry MJ et al.. “Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management.” The Journal of urology (2021). PMID: 34384237 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, History and Evolution of Treatment
  62. [62]

    Foster HE, Barry MJ, Dahm P et al.. “Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline.” The Journal of urology (2018). PMID: 29775639 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
  63. [63]

    Foster HE, Dahm P, Kohler TS et al.. “Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019.” The Journal of urology (2019). PMID: 31059668 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Endoscopic & Procedural Technique Considerations
  64. [64]

    Parsons JK, Schenk JM, Arnold KB et al.. “Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.” European urology (2012). PMID: 22459892 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical
  65. [65]

    Drake MJ, Chapple C, Sokol R et al.. “Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.” European urology (2014). PMID: 25070148 ↗

    L4RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompression
  66. [66]

    Roehrborn CG, Andriole GL, Wilson TH et al.. “Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.” European urology (2010). PMID: 21093145 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
  67. [67]

    Kaplan SA, Parekattil SJ, Wu NZ et al.. “12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia.” The Journal of urology (2025). PMID: 41396103 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical
  68. [68]

    Kramer JJ, Gu L, Moreira D et al.. “Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.” The Journal of urology (2021). PMID: 34544265 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors
  69. [69]

    Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A et al.. “Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.” BJU international (2018). PMID: 29694707 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors
  70. [70]

    Gacci M, Corona G, Sebastianelli A et al.. “Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis.” European urology (2016). PMID: 27451136 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, History and Evolution of Treatment, Complications
  71. [71]

    Benzouak T, Addar A, Prudencio-Brunello MA et al.. “Comparative Analysis of Holmium Laser Enucleation of the Prostate and Robotic-Assisted Simple Prostatectomy in Benign Prostatic Hyperplasia Management: A Systematic Review and Meta-Analysis.” The Journal of urology (2024). PMID: 39423101 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical
  72. [72]

    Bent S, Kane C, Shinohara K et al.. “Saw palmetto for benign prostatic hyperplasia.” The New England journal of medicine (2006). PMID: 16467543 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  73. [73]

    Andriole GL, Bostwick DG, Brawley OW et al.. “Effect of dutasteride on the risk of prostate cancer.” The New England journal of medicine (2010). PMID: 20357281 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  74. [74]

    Cindolo L, Pirozzi L, Fanizza C et al.. “Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.” European urology (2014). PMID: 25465970 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  75. [75]

    Pattanaik S, Mavuduru RS, Panda A et al.. “Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.” BJU international (2019). PMID: 30681264 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  76. [76]

    Lin Y, Wu X, Xu A et al.. “Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials.” World journal of urology (2015). PMID: 26699627 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors
  77. [77]

    Shamout S, Carlson K, Brotherhood HL et al.. “Incidence and predictors of early and late hospital readmission after transurethral resection of the prostate: a population-based cohort study.” BJU international (2020). PMID: 32790101 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors
  78. [78]

    Roehrborn CG, Nickel JC, Andriole GL et al.. “Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.” Urology (2011). PMID: 21764428 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors
  79. [79]

    Castellani D, Cormio A, Alberti A et al.. “Incidence of Overactive Bladder Symptoms and Dysuria Following Transurethral Interventions for Benign Prostatic Enlargement: A Systematic Review and Meta-Analysis of Comparative and Randomized Studies.” Neurourology and urodynamics (2025). PMID: 40831020 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  80. [80]

    Ozervarli MF, Oba KC, Yilmaz M et al.. “Minimally invasive treatments for benign prostatic hyperplasia in patients over 75: a systematic review.” World journal of urology (2025). PMID: 41251804 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History, Special Populations & Pregnancy
  81. [81]

    Titus RS, Bhatia A, Porto JG et al.. “Open simple prostatectomy in the last three decades: results of a meta-analysis.” World journal of urology (2024). PMID: 39499333 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
  82. [82]

    Castellani D, Wroclawski ML, Pirola GM et al.. “Bladder neck stenosis after transurethral prostate surgery: a systematic review and meta-analysis.” World journal of urology (2021). PMID: 33974100 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  83. [83]

    Chen L, Chen C, Li C et al.. “Low-power versus high-power laser for holmium laser enucleation of prostate: systematic review and meta-analysis.” World journal of urology (2025). PMID: 40244475 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Endoscopic & Procedural Technique Considerations
  84. [84]

    Liu L, Zheng S, Han P et al.. “Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.” Urology (2011). PMID: 21195830 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications
  85. [85]

    Fitzpatrick JM. “The natural history of benign prostatic hyperplasia.” BJU international (2006). PMID: 16507045 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompression, History and Evolution of Treatment, Prognosis & Natural History
  86. [86]

    Zheng R, Daniels JP, Mirocha JM et al.. “Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.” The Prostate (2026). PMID: 41821360 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  87. [87]

    Ritter M, Stein J, Barber N et al.. “WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms.” European urology focus (2026). PMID: 41638951 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  88. [88]

    Barashi NS, Pearce SM, Cohen AJ et al.. “Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study.” European urology oncology (2018). PMID: 31158094 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
  89. [89]

    Anract J, Klein C, Pinar U et al.. “Incidental Prostate Cancer in Patients Undergoing Surgery for Benign Prostatic Hyperplasia: A Predictive Model.” European urology oncology (2024). PMID: 39256094 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  90. [90]

    Ilic D, Forbes KM, Hassed C. “Lycopene for the prevention of prostate cancer.” The Cochrane database of systematic reviews (2011). PMID: 22071840 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
  91. [91]

    Wilt TJ, MacDonald R, Hagerty K et al.. “Five-alpha-reductase Inhibitors for prostate cancer prevention.” The Cochrane database of systematic reviews (2008). PMID: 18425978 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
  92. [92]

    Pattanaik S, Mavuduru RS, Panda A et al.. “Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2018). PMID: 30480763 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  93. [93]

    Lo Re M, Cadenar A, Pezzoli M et al.. “Effectiveness of contemporary treatments for iatrogenic urethral strictures following endoscopic management of benign prostatic hyperplasia: a comprehensive review.” World journal of urology (2026). PMID: 42165905 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Endoscopic & Procedural Technique Considerations, Complications, Prognosis & Natural History
  94. [94]

    Hao X, Wang S, Deng F et al.. “Robot-assisted simple prostatectomy vs. laser enucleation of the prostate for large-volume benign prostatic hyperplasia (BPH, ≥80 mL): a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42164167 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications
  95. [95]

    Bukyana S, Fillie PC, Kakooza J et al.. “Prevalence of erectile dysfunction in men with lower urinary tract symptoms/benign prostatic hyperplasia: a systematic review and meta-analysis.” Sexual medicine reviews (2026). PMID: 42117744 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  96. [96]

    Vasudevan V, Fernandez GM, Dunn RL et al.. “Relative Impact of Male Urinary Conditions on Overall Quality of Life.” Neurourology and urodynamics (2025). PMID: 40452415 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications
  97. [97]

    Papatsoris AG, Papapetropoulos S, Singer C et al.. “Urinary and erectile dysfunction in multiple system atrophy (MSA).” Neurourology and urodynamics (2008). PMID: 17563111 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
  98. [98]

    Tarcan T, Hashim H, Malde S et al.. “Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI-RS 2023.” Neurourology and urodynamics (2024). PMID: 38477358 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical
  99. [99]

    Nitti VW, Kohan A, McCammon K et al.. “Efficacy and safety of onabotulinumtoxinA for the treatment of overactive bladder in men and women: A pooled analysis.” Neurourology and urodynamics (2024). PMID: 38973548 ↗

    L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompression, Complications
  100. [100]

    Bravi F, Bosetti C, Dal Maso L et al.. “Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia.” Urology (2006). PMID: 16765180 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  101. [101]

    Fendereski K, Horns JJ, Dehghanbanadaki H et al.. “The Impact of Testosterone Therapy on Benign Prostatic Hyperplasia in Hypogonadal Males.” Urology (2024). PMID: 39550043 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  102. [102]

    St Sauver JL, Jacobson DJ, McGree ME et al.. “Longitudinal association between prostatitis and development of benign prostatic hyperplasia.” Urology (2008). PMID: 18342190 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  103. [103]

    Roehrborn CG, Siami P, Barkin J et al.. “The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.” European urology (2009). PMID: 19825505 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  104. [104]

    Staskin D, Owens-Grillo J, Thomas E et al.. “Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.” The Journal of urology (2024). PMID: 38708869 ↗

    L1RCTCited in: Clinical Presentation, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Complications
  105. [105]

    Kaplan SA, Moss J, Freedman S et al.. “The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.” The Journal of urology (2023). PMID: 37555604 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  106. [106]

    Parsons JK, Kashefi C. “Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms.” European urology (2008). PMID: 18358592 ↗

    L2SR_OBSCited in: Clinical Presentation
  107. [107]

    Serati M, Andersson KE, Dmochowski R et al.. “Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms.” European urology (2018). PMID: 30293906 ↗

    L1SR_OBSCited in: Clinical Presentation, Complications
  108. [108]

    Franco JVA, Jung JH, Imamura M et al.. “Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network meta-analysis.” BJU international (2021). PMID: 34820997 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Prognosis & Natural History
  109. [109]

    Gacci M, Corona G, Vignozzi L et al.. “Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis.” BJU international (2014). PMID: 24602293 ↗

    L2SR_OBSCited in: Clinical Presentation
  110. [110]

    Hollands C, Gray D, Marren A et al.. “Empowering patient choice: a systematic review of decision aids for benign prostatic hyperplasia.” BJU international (2025). PMID: 40420675 ↗

    L1SR_OBSCited in: Clinical Presentation
  111. [111]

    McVary KT, Rogers T, Roehrborn CG. “Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study.” Urology (2019). PMID: 30677455 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  112. [112]

    Long B, Cheema A, Copelan O et al.. “Five-Year Outcomes of Water Vapor Therapy vs Doxazosin, Finasteride, and Combination Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Cohort Data From the Medical Therapy of Prostatic Symptoms Trial.” Urology (2025). PMID: 40683564 ↗

    L2RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  113. [113]

    Pina-Vaz T, Silva AC, Silva C et al.. “The urinary and prostatic microbiome in non-neurogenic male LUTS/BPH: A systematic review.” Neurourology and urodynamics (2024). PMID: 38934484 ↗

    L2SR_OBSCited in: Clinical Presentation, Prognosis & Natural History
  114. [114]

    Herschorn S, Tarcan T, Jiang YH et al.. “Safety and efficacy of an α1 -blocker plus mirabegron compared with an α1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis.” Neurourology and urodynamics (2024). PMID: 38291827 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Acute Management & Decompression, Complications, Prognosis & Natural History
  115. [115]

    Burke CA, Nitti VW, Stothers L. “Melatonin and melatonin receptor agonists in the treatment of nocturia: A systematic review.” Neurourology and urodynamics (2024). PMID: 38456646 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Prognosis & Natural History
  116. [116]

    Porto JG, Bhatia AM, Bhat A et al.. “Evaluating transurethral resection of the prostate over twenty years: a systematic review and meta-analysis of randomized clinical trials.” World journal of urology (2024). PMID: 39547977 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Acute Management & Decompression, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Complications, Prognosis & Natural History
  117. [117]

    Akgul B, Tozsin A, Aydın A et al.. “Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.” World journal of urology (2025). PMID: 40817983 ↗

    L2SR_OBSCited in: Clinical Presentation
  118. [118]

    Bhojani N, Bidair M, Zorn KC et al.. “Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results.” Urology (2019). PMID: 31059728 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis & Workup, Endoscopic & Procedural Technique Considerations, Complications, Prognosis & Natural History
  119. [119]

    Wu XJ, Zhi Y, Zheng J et al.. “Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients.” Urology (2013). PMID: 24246318 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Acute Management & Decompression
  120. [120]

    Kathrins M, Doersch K, Nimeh T et al.. “The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review.” Urology (2015). PMID: 26616095 ↗

    L2SR_OBSCited in: Clinical Presentation
  121. [121]

    Launer BM, McVary KT, Ricke WA et al.. “The rising worldwide impact of benign prostatic hyperplasia.” BJU international (2020). PMID: 33124118 ↗

    L2OTHERCited in: Clinical Presentation
  122. [122]

    Bauer SR, Kenfield SA, Oni-Orisan A et al.. “Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42406401 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  123. [123]

    Spezzi Roncero LG, Montelli Yanzi G, Cristallo C et al.. “Modified HoLEP technique: does it preserve ejaculation?” World journal of urology (2026). PMID: 42373859 ↗

    L1RCTCited in: Clinical Presentation, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
  124. [124]

    Mouli S, Dolmatch BL, Gunn AJ et al.. “Society of Interventional Radiology (SIR) 2026 Practice Guidance Document for Prostatic Artery Embolization.” Journal of vascular and interventional radiology : JVIR (2026). PMID: 42223385 ↗

    L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
  125. [125]

    Johnson EE, Mamoulakis C, Stoniute A et al.. “Conservative interventions for managing urinary incontinence after prostate surgery.” The Cochrane database of systematic reviews (2023). PMID: 37070660 ↗

    L1SR_OBSCited in: Clinical Presentation, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Complications
  126. [126]

    Tacklind J, Fink HA, Macdonald R et al.. “Finasteride for benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2010). PMID: 20927745 ↗

    L1SR_OBSCited in: Clinical Presentation, Acute Management & Decompression, Prognosis & Natural History
  127. [127]

    Wilt TJ, Macdonald R, Ishani A et al.. “WITHDRAWN: Cernilton for benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2011). PMID: 21563128 ↗

    L1SR_OBSCited in: Clinical Presentation, History and Evolution of Treatment
  128. [128]

    Tacklind J, Macdonald R, Rutks I et al.. “Serenoa repens for benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2012). PMID: 23235581 ↗

    L1SR_OBSCited in: Clinical Presentation
  129. [129]

    Wilt TJ, Macdonald R, Rutks I. “WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2011). PMID: 21901681 ↗

    L1SR_OBSCited in: Clinical Presentation, History and Evolution of Treatment, Prognosis & Natural History
  130. [130]

    Siqueira MHB, Aldoukhi M, Bhojani N et al.. “Predictors of surgical retreatment following Rezūm water vapor therapy: a multi-center real-world cohort study.” World journal of urology (2026). PMID: 42371095 ↗

    L2COHORTCited in: Clinical Presentation
  131. [131]

    Vincent MW, Gilling PJ. “HoLEP has come of age.” World journal of urology (2014). PMID: 25416347 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term & Definitive Management: Medical vs Endourologic/Surgical
  132. [132]

    Yogiswara N, Rizaldi F, Soebadi MA. “The role of supramontanal preservation in ejaculation-sparing after transurethral resection of the prostate: A systematic review and meta-analysis.” Central European journal of urology (2026). PMID: 42375726 ↗

    L1SR_OBSCited in: Clinical Presentation
  133. [133]

    Gilling P, Barber N, Bidair M et al.. “WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia.” The Journal of urology (2018). PMID: 29360529 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Complications, Prognosis & Natural History
  134. [134]

    Ficarra V, Romito I, Sorce G et al.. “Comparison of Single- and Multiport Robot-assisted Approaches in Prostate and Renal Surgery: A Systematic Review and Meta-analysis.” European urology (2025). PMID: 41016915 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
  135. [135]

    Perera M, Roberts MJ, Doi SA et al.. “Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis.” European urology (2014). PMID: 25466940 ↗

    L1SR_OBSCited in: Diagnosis & Workup
  136. [136]

    Dahm P, Brasure M, MacDonald R et al.. “Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.” European urology (2016). PMID: 27717522 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Prognosis & Natural History
  137. [137]

    Gacci M, Corona G, Salvi M et al.. “A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.” European urology (2012). PMID: 22405510 ↗

    L1SR_OBSCited in: Diagnosis & Workup
  138. [138]

    Shim SR, Kanhai KJ, Ko YM et al.. “Efficacy and Safety of Prostatic Arterial Embolization: Systematic Review with Meta-Analysis and Meta-Regression.” The Journal of urology (2016). PMID: 27592008 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Prognosis & Natural History
  139. [139]

    Armitage JN, Cathcart PJ, Rashidian A et al.. “Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature.” The Journal of urology (2007). PMID: 17437773 ↗

    L4SR_OBSCited in: Diagnosis & Workup, Prognosis & Natural History
  140. [140]

    Lenfant L, Pinar U, Roupret M et al.. “Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis.” The Journal of urology (2022). PMID: 36395428 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Acute Management & Decompression, Prognosis & Natural History
  141. [141]

    Lee SW, Lee SH, Kim JH et al.. “Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial.” BJU international (2026). PMID: 41667130 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  142. [142]

    Desai M, Bidair M, Bhojani N et al.. “WATER II (80-150 mL) procedural outcomes.” BJU international (2018). PMID: 29694702 ↗

    L4TRIAL_NONRANDOMCited in: Diagnosis & Workup, Complications
  143. [143]

    MacDonald R, Tacklind JW, Rutks I et al.. “Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.” BJU international (2012). PMID: 22551330 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Prognosis & Natural History
  144. [144]

    Hagovska M, Svihra J, Macko L et al.. “The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder.” World journal of urology (2024). PMID: 38698269 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
  145. [145]

    Tawfik A, Abo-Elenen M, Gaber M et al.. “Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes.” World journal of urology (2024). PMID: 38308714 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  146. [146]

    Tong Z, Yang Z, Dong B et al.. “Efficacy and Safety of High-Frequency Irreversible Electroporation in Benign Prostatic Hyperplasia: A Randomized Controlled, Open-label, Multi-Center Clinical Study.” Urology (2025). PMID: 40122290 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  147. [147]

    Peters KM, Owens-Grillo J, Thomas E et al.. “Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.” Urology (2025). PMID: 40902908 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Complications, Prognosis & Natural History
  148. [148]

    Altieri VM, Di Bello F, Saldutto P et al.. “Outcomes and safety of trans perineal laser ablation of the prostate: a systematic review.” World journal of urology (2025). PMID: 40548982 ↗

    L4SR_OBSCited in: Diagnosis & Workup, Complications
  149. [149]

    Eredics K, Madersbacher S, Schauer I. “A Relevant Midterm (12 Months) Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Rate in Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia-A Meta-analysis.” Urology (2017). PMID: 28506862 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Prognosis & Natural History
  150. [150]

    Jung JH, McCutcheon KA, Borofsky M et al.. “Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review.” BJU international (2022). PMID: 35696302 ↗

    L2REVIEW_NARRATIVECited in: Diagnosis & Workup
  151. [151]

    Han TM, Helon J, Long B et al.. “Sexual function outcomes of the 5-year treatment with Rezum compared to doxazosin, finasteride, and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms Trial.” The journal of sexual medicine (2026). PMID: 42117741 ↗

    L2RCTCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
  152. [152]

    Tacklind J, MacDonald R, Rutks I et al.. “Serenoa repens for benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2009). PMID: 19370565 ↗

    L1SR_OBSCited in: Diagnosis & Workup
  153. [153]

    Hwang EC, Jung JH, Borofsky M et al.. “Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2019). PMID: 30759311 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Endoscopic & Procedural Technique Considerations
  154. [154]

    Jung JH, McCutcheon KA, Borofsky M et al.. “Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2020). PMID: 33368143 ↗

    L1SR_OBSCited in: Diagnosis & Workup
  155. [155]

    Sze C, Zhang TR, Dreyfuss L et al.. “US patterns of care for urodynamic evaluation for BPH.” Neurourology and urodynamics (2023). PMID: 37395472 ↗

    L2OTHERCited in: Diagnosis & Workup
  156. [156]

    Marchal C, Perez JE, Herrera B et al.. “The use of botulinum toxin in benign prostatic hyperplasia.” Neurourology and urodynamics (2011). PMID: 21905088 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup
  157. [157]

    De Nunzio C, Autorino R, Bachmann A et al.. “The diagnosis of benign prostatic obstruction: Development of a clinical nomogram.” Neurourology and urodynamics (2014). PMID: 25524269 ↗

    L2OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
  158. [158]

    Andersson KE, de Groat WC, McVary KT et al.. “Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.” Neurourology and urodynamics (2011). PMID: 21284024 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup
  159. [159]

    Zhao N, Tian E. “Effect of mind map-guided nursing on pain control after transurethral resection of the prostate.” Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas (2026). PMID: 42018813 ↗

    L1RCTCited in: Diagnosis & Workup
  160. [160]

    So SW, Lee H, Lee G et al.. “Effect of Urodynamic Bladder Outlet Obstruction on Bladder Trabeculation Grade in Patients With Benign Prostatic Hyperplasia: Retrospective Patient Cohort Study.” International neurourology journal (2026). PMID: 42415606 ↗

    L2COHORTCited in: Diagnosis & Workup
  161. [161]

    Abrams P, Chapple C, Khoury S et al.. “Evaluation and treatment of lower urinary tract symptoms in older men.” The Journal of urology (2013). PMID: 23234640 ↗

    L1GUIDELINECited in: Severity, Staging & Risk Stratification, Complications
  162. [162]

    Enikeev D, Rapoport L, Gazimiev M et al.. “Monopolar enucleation versus transurethral resection of the prostate for small- and medium-sized (< 80 cc) benign prostate hyperplasia: a prospective analysis.” World journal of urology (2019). PMID: 30963229 ↗

    L2RCTCited in: Severity, Staging & Risk Stratification
  163. [163]

    Gravas S, Samarinas M, Zacharouli K et al.. “The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study.” World journal of urology (2018). PMID: 30027406 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification
  164. [164]

    Zlotta AR, Egawa S, Pushkar D et al.. “Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men.” European urology (2014). PMID: 25012523 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  165. [165]

    Trojan L, Bode C, Weiss C et al.. “IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.” European urology (2005). PMID: 16386354 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification
  166. [166]

    Simone G, Misuraca L, Anceschi U et al.. “Urethra and Ejaculation Preserving Robot-assisted Simple Prostatectomy: Near-infrared Fluorescence Imaging-guided Madigan Technique.” European urology (2018). PMID: 30553615 ↗

    L5OTHERCited in: Severity, Staging & Risk Stratification
  167. [167]

    Tomas D, Kruslin B, Rogatsch H et al.. “Different types of atrophy in the prostate with and without adenocarcinoma.” European urology (2006). PMID: 16824675 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification
  168. [168]

    Pantuck AJ, Baniel J, Kirkali Z et al.. “A novel resectoscope for transurethral resection of bladder tumors and the prostate.” The Journal of urology (2007). PMID: 17936809 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification
  169. [169]

    Seki N, Nomura H, Yamaguchi A et al.. “Effects of photoselective vaporization of the prostate on urodynamics in patients with benign prostatic hyperplasia.” The Journal of urology (2008). PMID: 18639299 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification
  170. [170]

    Kaplan SA, Kohler TS, Kausik SJ. “Noninvasive Pressure Flow Studies in the Evaluation of Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Review of 50,000 Patients.” The Journal of urology (2020). PMID: 32568608 ↗

    L2REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
  171. [171]

    Jeldres C, Isbarn H, Capitanio U et al.. “Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia.” The Journal of urology (2009). PMID: 19535100 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  172. [172]

    Fitzpatrick JM, Banu E, Oudard S. “Prostate-specific antigen kinetics in localized and advanced prostate cancer.” BJU international (2009). PMID: 19210674 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
  173. [173]

    Emberton M, Fitzpatrick JM, Rees J. “Risk stratification for benign prostatic hyperplasia (BPH) treatment.” BJU international (2011). PMID: 21265993 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Acute Management & Decompression
  174. [174]

    Schwarzenbach H, Chun FK, Müller I et al.. “Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.” BJU international (2008). PMID: 18336598 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification
  175. [175]

    Trojan L, Rensch F, Voss M et al.. “The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer.” BJU international (2006). PMID: 16978291 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification
  176. [176]

    Westbrook P, Farooq A, Venkatraman G et al.. “A systematic review of associations-exploring whether prostate size is related to sexual function outcomes following water vapor thermal therapy.” Sexual medicine reviews (2026). PMID: 41722093 ↗

    L2SR_OBSCited in: Severity, Staging & Risk Stratification
  177. [177]

    Li H, Zhang Y, Chen L et al.. “Plasma proteomic signatures predict incident benign prostatic hyperplasia: a prospective cohort study of 20 996 men.” Journal of global health (2026). PMID: 42281484 ↗

    L2COHORTCited in: Severity, Staging & Risk Stratification, Special Populations & Pregnancy
  178. [178]

    Liang S, Lao Y, Ma P et al.. “Development and interpretability of a machine learning-derived model for the identification of latent prostate cancer in patients initially diagnosed with benign prostatic hyperplasia: a retrospective cohort study.” BMC medical informatics and decision making (2026). PMID: 42260550 ↗

    L2COHORTCited in: Severity, Staging & Risk Stratification
  179. [179]

    Li X, Lian P, Chen H et al.. “Phenotypic age acceleration as a novel predictor of benign prostatic hyperplasia: a prospective cohort study.” GeroScience (2025). PMID: 40931290 ↗

    L4COHORTCited in: Severity, Staging & Risk Stratification
  180. [180]

    Berto FG, McClure JA, Campbell J et al.. “Use of alpha-adrenergic antagonists for lower urinary tract symptoms is not associated with worsening cognitive function.” Neurourology and urodynamics (2024). PMID: 38803218 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  181. [181]

    van Dort W, Rosier PFWM, Geurts BJ et al.. “Quantifying bladder outflow obstruction in men: A comparison of four approximation methods exploiting large data samples.” Neurourology and urodynamics (2023). PMID: 37614044 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification
  182. [182]

    Oelke M, Rademakers KL, van Koeveringe GA. “Unravelling detrusor underactivity: Development of a bladder outlet resistance-Bladder contractility nomogram for adult male patients with lower urinary tract symptoms.” Neurourology and urodynamics (2015). PMID: 26235823 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  183. [183]

    Wada N, Kita M, Hashizume K et al.. “Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.” Neurourology and urodynamics (2013). PMID: 23861329 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification
  184. [184]

    Li X, He F, Huang C et al.. “Development and validation of a nomogram for predicting early stress urinary incontinence following endoscopic enucleation of the prostate.” World journal of urology (2021). PMID: 33475762 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  185. [185]

    Labban M, Frego N, Qian Z et al.. “Does the 5-item Frailty Index predict surgical complications of endoscopic surgical management for benign prostatic obstruction? An analysis of the ACS-NSQIP.” World journal of urology (2022). PMID: 36125504 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  186. [186]

    De Nunzio C, Cantiello F, Fiori C et al.. “Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study.” World journal of urology (2020). PMID: 32851439 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification
  187. [187]

    Li L, Dong A, Liu K et al.. “Frailty and frailty progression in relation to the risk of benign prostatic hyperplasia/lower urinary tract symptoms among Chinese middle-aged and older men: a prospective cohort study.” The aging male : the official journal of the International Society for the Study of the Aging Male (2026). PMID: 41793280 ↗

    L2COHORTCited in: Severity, Staging & Risk Stratification
  188. [188]

    Lee EY, Kim JH, Park JW et al.. “Clinical Characteristics of Complex Karyotype Soft Tissue Sarcomas: A Single-Institution Cohort Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752671 ↗

    L4COHORTCited in: Severity, Staging & Risk Stratification
  189. [189]

    Slawin KM, Kattan MW, Roehrborn CG et al.. “Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia.” Urology (2006). PMID: 16413338 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  190. [190]

    Kaplan SA, He W, Koltun WD et al.. “Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.” European urology (2012). PMID: 22831853 ↗

    L1RCTCited in: Acute Management & Decompression
  191. [191]

    Autorino R, Damiano R, Di Lorenzo G et al.. “Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate.” European urology (2009). PMID: 19185975 ↗

    L1RCTCited in: Acute Management & Decompression
  192. [192]

    Filson CP, Hollingsworth JM, Clemens JQ et al.. “The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis.” The Journal of urology (2013). PMID: 23727412 ↗

    L1SR_OBSCited in: Acute Management & Decompression
  193. [193]

    Emberton M, Fitzpatrick JM, Garcia-Losa M et al.. “Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials.” BJU international (2008). PMID: 18549433 ↗

    L2TRIAL_NONRANDOMCited in: Acute Management & Decompression, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
  194. [194]

    Elterman D, Bhojani N, Vannabouathong C et al.. “Rezūm therapy for ≥80-mL benign prostatic enlargement: a large, multicentre cohort study.” BJU international (2022). PMID: 35466513 ↗

    L2COHORTCited in: Acute Management & Decompression, History and Evolution of Treatment
  195. [195]

    Schelin S, Geertsen U, Walter S et al.. “Feedback microwave thermotherapy versus TURP/prostate enucleation surgery in patients with benign prostatic hyperplasia and persistent urinary retention: a prospective, randomized, controlled, multicenter study.” Urology (2006). PMID: 17070355 ↗

    L1SR_MA_RCTCited in: Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical
  196. [196]

    Chung SD, Chang HC, Chiu B et al.. “The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.” Neurourology and urodynamics (2011). PMID: 21344494 ↗

    L1RCTCited in: Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  197. [197]

    MacDiarmid SA, Ellsworth PI, Ginsberg DA et al.. “Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.” Urology (2010). PMID: 20970833 ↗

    L1RCTCited in: Acute Management & Decompression
  198. [198]

    Sciarra A, Di Silverio F, Salciccia S et al.. “Inflammation and chronic prostatic diseases: evidence for a link?” European urology (2007). PMID: 17618043 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Decompression, Prevention, Screening & Surveillance
  199. [199]

    Ramos R, Ferguson E, Abou Zeinab M et al.. “Single-port Transvesical Robot-Assisted Simple Prostatectomy: Surgical Technique and Clinical Outcomes.” European urology (2023). PMID: 38057210 ↗

    L4OTHERCited in: Acute Management & Decompression
  200. [200]

    Sotelo R, Clavijo R, Carmona O et al.. “Robotic simple prostatectomy.” The Journal of urology (2008). PMID: 18076926 ↗

    L4OTHERCited in: Acute Management & Decompression
  201. [201]

    Marks LS, Roehrborn CG, Andriole GL. “Prevention of benign prostatic hyperplasia disease.” The Journal of urology (2006). PMID: 16952616 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Decompression
  202. [202]

    McVary KT. “Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.” The Journal of urology (2006). PMID: 16406865 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Decompression
  203. [203]

    Pyrgidis N, Weinhold P, Schulz GB et al.. “Peri-operative outcomes of open, laparoscopic and robotic simple prostatectomy.” BJU international (2025). PMID: 40955513 ↗

    L3OTHERCited in: Acute Management & Decompression
  204. [204]

    Roehrborn CG. “Definition of at-risk patients: baseline variables.” BJU international (2006). PMID: 16507046 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Decompression, History and Evolution of Treatment
  205. [205]

    Emberton M. “Definition of at-risk patients: dynamic variables.” BJU international (2006). PMID: 16507047 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Decompression
  206. [206]

    Hwang EC, Gandhi S, Jung JH et al.. “Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2018). PMID: 30306544 ↗

    L1SR_OBSCited in: Acute Management & Decompression
  207. [207]

    Giulioni C, Cafarelli A, Falsetti F et al.. “Perioperative outcomes of ongoing antithrombotic therapy during endoscopic surgery for benign prostatic hyperplasia: a systematic review and meta-analysis of observational studies.” Prostate cancer and prostatic diseases (2026). PMID: 41781484 ↗

    L2SR_OBSCited in: Acute Management & Decompression
  208. [208]

    Castellani D, Akand M, Giulioni C et al.. “Incidence of Acute Urinary Retention/Failure to Void after Transurethral Interventions for Benign Prostatic Enlargement: Results from a Systematic Review and Meta-Analysis of Comparative Randomized Studies by the FUTURE Collaborative of the Endourological Society.” Journal of endourology (2026). PMID: 41640376 ↗

    L1SR_OBSCited in: Acute Management & Decompression
  209. [209]

    Rahematpura S, Marantidis J, Wibben A et al.. “Using intravesical botulinum toxin as an adjunct during urologic surgery: a systematic review.” World journal of urology (2026). PMID: 41609877 ↗

    L2SR_OBSCited in: Acute Management & Decompression
  210. [210]

    Pinar U, Gas J, Sarrazin C et al.. “Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH).” The French journal of urology (2025). PMID: 41271374 ↗

    L1GUIDELINECited in: Acute Management & Decompression, Special Populations & Pregnancy
  211. [211]

    Sotelo RJ, Astigueta JC, Desai MM et al.. “Laparoendoscopic single-site surgery simple prostatectomy: initial report.” Urology (2009). PMID: 19604561 ↗

    L4CASE_REPORTCited in: Acute Management & Decompression
  212. [212]

    Abello A, DeWolf WC, Das AK. “Expectant long-term follow-up of patients with chronic urinary retention.” Neurourology and urodynamics (2018). PMID: 30407653 ↗

    L2OTHERCited in: Acute Management & Decompression, Endoscopic & Procedural Technique Considerations
  213. [213]

    Kronenberg P. “Alpha-blockers: the magic pill for endourology-The great delusion.” World journal of urology (2024). PMID: 38421483 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical
  214. [214]

    Pirola GM, Castellani D, Naselli A et al.. “Endoscopic enucleation of the prostate in men aged 80 years and older. Outcomes from a global, large, and multicenter series using different energy sources and techniques.” World journal of urology (2025). PMID: 40448729 ↗

    L3OTHERCited in: Acute Management & Decompression, Special Populations & Pregnancy
  215. [215]

    De Nunzio C, Salonia A, Gacci M et al.. “Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.” World journal of urology (2020). PMID: 32060633 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Decompression
  216. [216]

    Gravas S, Oelke M. “Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.” World journal of urology (2009). PMID: 19956956 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Decompression
  217. [217]

    Aho T, Finch W, Jefferson P et al.. “HoLEP for acute and non-neurogenic chronic urinary retention: how effective is it?” World journal of urology (2021). PMID: 33763730 ↗

    L3OTHERCited in: Acute Management & Decompression
  218. [218]

    Sandhu JS, Breyer B, Comiter C et al.. “Incontinence after Prostate Treatment: AUA/SUFU Guideline.” The Journal of urology (2019). PMID: 31059663 ↗

    L1GUIDELINECited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Complications
  219. [219]

    Pisco JM, Bilhim T, Costa NV et al.. “Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia.” European urology (2019). PMID: 31831295 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Complications
  220. [220]

    Sønksen J, Barber NJ, Speakman MJ et al.. “Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study.” European urology (2015). PMID: 25937539 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  221. [221]

    Abt D, Müllhaupt G, Hechelhammer L et al.. “Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial.” European urology (2021). PMID: 33612376 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  222. [222]

    Marberger M, Chartier-Kastler E, Egerdie B et al.. “A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.” European urology (2012). PMID: 23098762 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  223. [223]

    McVary KT, Gittelman MC, Goldberg KA et al.. “Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.” The Journal of urology (2021). PMID: 33872051 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  224. [224]

    Reich O, Gratzke C, Stief CG. “Techniques and long-term results of surgical procedures for BPH.” European urology (2006). PMID: 16481092 ↗

    L5SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
  225. [225]

    Veccia A, Antonelli A, Francavilla S et al.. “Minimally Invasive Radical Prostatectomy after Previous Bladder Outlet Surgery: A Systematic Review and Pooled Analysis of Comparative Studies.” The Journal of urology (2019). PMID: 31039100 ↗

    L2SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  226. [226]

    Bertolo R, Iacovelli V, Cipriani C et al.. “Ejaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: a randomized trial.” BJU international (2023). PMID: 36917033 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
  227. [227]

    Horváth K, Walter G, Varga A et al.. “A novel approach to the treatment of benign prostatic hyperplasia.” BJU international (2006). PMID: 16686721 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Complications
  228. [228]

    Abt D, Müllhaupt G, Mordasini L et al.. “Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non-inferiority trial.” BJU international (2018). PMID: 30499637 ↗

    L2RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  229. [229]

    Nickel JC, Gilling P, Tammela TL et al.. “Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).” BJU international (2011). PMID: 21631695 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  230. [230]

    Wu SW, Tseng CS, Yuan LH et al.. “Prospective study of urinary incontinence recovery following endoscopic enucleation of the prostate.” BJU international (2024). PMID: 39030920 ↗

    L2COHORTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  231. [231]

    Yamanishi T, Kaga K, Sakata K et al.. “A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).” Neurourology and urodynamics (2020). PMID: 31961963 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Complications
  232. [232]

    Matsukawa Y, Takai S, Majima T et al.. “Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.” Neurourology and urodynamics (2019). PMID: 30779375 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  233. [233]

    Matsukawa Y, Takai S, Funahashi Y et al.. “Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.” Neurourology and urodynamics (2016). PMID: 27060991 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  234. [234]

    Totaro A, Pinto F, Pugliese D et al.. “Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.” Neurourology and urodynamics (2017). PMID: 28840969 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  235. [235]

    Shorbagy AA, Ismail M, Kotb YM et al.. “Laser vs. bipolar prostate vaporization in bleeding-prone patients: a randomized trial and cutting-edge analysis.” World journal of urology (2025). PMID: 40407947 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  236. [236]

    El-Shaer W, Abd-Allah AR, El-Shafie MF et al.. “Evaluation of the Therapeutic Potential of Garcinia cambogia Alone or in Combination With Silodosin in the Management of LUTS/BPH: A Prospective Randomized Controlled Study.” Urology (2025). PMID: 40209997 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  237. [237]

    Ozdemir I, Bozkurt O, Demir O et al.. “Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms.” Urology (2009). PMID: 19501883 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  238. [238]

    Lekas AG, Lazaris AC, Chrisofos M et al.. “Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.” Urology (2006). PMID: 16904480 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  239. [239]

    Tong Z, Sherryn S, Xia S et al.. “MOSES™ Technology vs Non-Moses Holmium Laser Enucleation of the Prostate: A Randomized Controlled Trial From a High-Volume Center.” Urology (2024). PMID: 38490277 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  240. [240]

    Assad A, Nguyen DD, Barber N et al.. “WATER vs WATER II 3-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80 cc and 80-150 cc Prostates.” Urology (2022). PMID: 35469810 ↗

    L2RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  241. [241]

    Lucca I, Shariat SF, Hofbauer SL et al.. “Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis.” World journal of urology (2014). PMID: 24879405 ↗

    L2SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
  242. [242]

    Bhat A, Blachman-Braun R, Herrmann TRW et al.. “Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.” World journal of urology (2021). PMID: 34212237 ↗

    L5SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Prevention, Screening & Surveillance
  243. [243]

    Kuntz RM. “Current role of lasers in the treatment of benign prostatic hyperplasia (BPH).” European urology (2006). PMID: 16632179 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  244. [244]

    Gravas S, Bachmann A, Reich O et al.. “Critical review of lasers in benign prostatic hyperplasia (BPH).” BJU international (2011). PMID: 21438974 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
  245. [245]

    Chen C, Hong X, Lin T et al.. “Comprehensive analysis of KAP nursing model combined with digital health management on postoperative self-management in BPH patients.” Frontiers in public health (2026). PMID: 41668860 ↗

    L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
  246. [246]

    Franco JV, Jung JH, Imamura M et al.. “Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis.” The Cochrane database of systematic reviews (2021). PMID: 34693990 ↗

    L1SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  247. [247]

    Hu S, Huang R, Keller P et al.. “Selective inhibition of neurogenic, but not agonist-induced contractions by phospholipase A2 inhibitors points to presynaptic phospholipase A2 functions in contractile neurotransmission to human prostate smooth muscle.” Neurourology and urodynamics (2023). PMID: 37583250 ↗

    L5OTHERCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  248. [248]

    Stadelmeier LF, Lederer E, Heimke F et al.. “Adjustable TransObturator Male System (ATOMS) After Desobstructive Surgery for Benign Prostatic Hyperplasia - Does the Type of Desobstructive Surgery Make a Difference?” Neurourology and urodynamics (2026). PMID: 41549527 ↗

    L4OTHERCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
  249. [249]

    Kuntz RM. “Laser treatment of benign prostatic hyperplasia.” World journal of urology (2007). PMID: 17530259 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  250. [250]

    Ditonno F, Franco A, Manfredi C et al.. “Single-port robot-assisted simple prostatectomy: techniques and outcomes.” World journal of urology (2024). PMID: 38393399 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
  251. [251]

    Moore E, Bracken B, Bremner W et al.. “Proscar: five-year experience.” European urology (1995). PMID: 8575497 ↗

    L4RCTCited in: History and Evolution of Treatment
  252. [252]

    Matzkin H, Soloway MS, Rangel MC et al.. “Efficacy of terazosin in patients with benign prostatic hyperplasia.” European urology (1992). PMID: 1379921 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  253. [253]

    Kang D, Andriole GL, Van De Vooren RC et al.. “Risk behaviours and benign prostatic hyperplasia.” BJU international (2004). PMID: 15180615 ↗

    L3RCTCited in: History and Evolution of Treatment
  254. [254]

    Berges RR, Kassen A, Senge T. “Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.” BJU international (2000). PMID: 10792163 ↗

    L4RCTCited in: History and Evolution of Treatment
  255. [255]

    McConnell JD, Roehrborn CG, Bautista OM et al.. “The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.” The New England journal of medicine (2003). PMID: 14681504 ↗

    L1RCTCited in: History and Evolution of Treatment
  256. [256]

    Gormley GJ, Stoner E, Bruskewitz RC et al.. “The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.” The New England journal of medicine (1992). PMID: 1383816 ↗

    L1RCTCited in: History and Evolution of Treatment
  257. [257]

    Wasson JH, Reda DJ, Bruskewitz RC et al.. “A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.” The New England journal of medicine (1995). PMID: 7527493 ↗

    L1RCTCited in: History and Evolution of Treatment
  258. [258]

    Lepor H, Williford WO, Barry MJ et al.. “The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.” The New England journal of medicine (1996). PMID: 8684407 ↗

    L1RCTCited in: History and Evolution of Treatment
  259. [259]

    McConnell JD, Bruskewitz R, Walsh P et al.. “The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.” The New England journal of medicine (1998). PMID: 9475762 ↗

    L1RCTCited in: History and Evolution of Treatment
  260. [260]

    Berges RR, Windeler J, Trampisch HJ et al.. “Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.” Lancet (London, England) (1995). PMID: 7540705 ↗

    L1RCTCited in: History and Evolution of Treatment
  261. [261]

    Andriole GL, Roehrborn C, Schulman C et al.. “Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.” Urology (2004). PMID: 15351586 ↗

    L1SR_MA_RCTCited in: History and Evolution of Treatment
  262. [262]

    Viitala A, Anttinen M, Wright C et al.. “Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study.” BJU international (2021). PMID: 34161649 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment, Complications
  263. [263]

    Da Silva FC. “Benign prostatic hyperplasia: natural evolution versus medical treatment.” European urology (1997). PMID: 9248811 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  264. [264]

    Boccon-Gibod L. “Benign prostatic hyperplasia: surgical versus nonsurgical treatment. A critical review.” European urology (1991). PMID: 1722164 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  265. [265]

    Anderson JB, Roehrborn CG, Schalken JA et al.. “The progression of benign prostatic hyperplasia: examining the evidence and determining the risk.” European urology (2001). PMID: 11306876 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  266. [266]

    Andersen JT. “Benign prostatic hyperplasia: symptoms and objective interpretation.” European urology (1991). PMID: 1722160 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  267. [267]

    Gratzke C, Bachmann A, Descazeaud A et al.. “EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.” European urology (2015). PMID: 25613154 ↗

    L1REVIEW_NARRATIVECited in: History and Evolution of Treatment
  268. [268]

    Bechis SK, Otsetov AG, Ge R et al.. “Personalized medicine for the management of benign prostatic hyperplasia.” The Journal of urology (2014). PMID: 24582540 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  269. [269]

    Sarma AV, Parsons JK, McVary K et al.. “Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know?” The Journal of urology (2009). PMID: 19846144 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  270. [270]

    Porru D, Campus G, Caria A et al.. “Impact of early pelvic floor rehabilitation after transurethral resection of the prostate.” Neurourology and urodynamics (2001). PMID: 11135382 ↗

    L1RCTCited in: History and Evolution of Treatment
  271. [271]

    Klingler HC, Madersbacher S, Schmidbauer CP. “Impact of different sized catheters on pressure-flow studies in patients with benign prostatic hyperplasia.” Neurourology and urodynamics (1996). PMID: 8857615 ↗

    L1RCTCited in: History and Evolution of Treatment
  272. [272]

    Giuliano F. “Impact of medical treatments for benign prostatic hyperplasia on sexual function.” BJU international (2006). PMID: 16507052 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  273. [273]

    Nakai H, Yamanishi T, Yasuda K et al.. “Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia.” Neurourology and urodynamics (2004). PMID: 15382181 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  274. [274]

    Isaacs JT. “Etiology of benign prostatic hyperplasia.” European urology (1994). PMID: 7507055 ↗

    L5OTHERCited in: History and Evolution of Treatment
  275. [275]

    McNaughton C, Mac Donald R, Wilt T. “Interventions for chronic abacterial prostatitis.” The Cochrane database of systematic reviews (2001). PMID: 11279750 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  276. [276]

    Wang X, Su Y, Yang C et al.. “Benign prostatic hyperplasia and cardiovascular risk: a prospective study among Chinese men.” World journal of urology (2021). PMID: 34426873 ↗

    L2COHORTCited in: History and Evolution of Treatment
  277. [277]

    Cohn JA. “Urodynamics in the Evaluation and Management of Bothersome Lower Urinary Tract Symptoms in Men With a Prostate.” Neurourology and urodynamics (2025). PMID: 40364603 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  278. [278]

    Christidis D, Clarebrough E, Ly V et al.. “Prostatic artery embolization for benign prostatic obstruction: assessment of safety and efficacy.” World journal of urology (2018). PMID: 29445846 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  279. [279]

    Yarnell E. “Botanical medicines for the urinary tract.” World journal of urology (2002). PMID: 12522584 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  280. [280]

    Madsen FA, Bruskewitz RC. “Cystoscopy in the evaluation of benign prostatic hyperplasia.” World journal of urology (1995). PMID: 7539675 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  281. [281]

    Le Guévelou J, Mathieu R, Peyrottes A et al.. “Tailoring prostate cancer external beam radiotherapy for patients with lower urinary tract symptoms.” World journal of urology (2025). PMID: 40481864 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  282. [282]

    Suarez-Ibarrola R, Miernik A, Gratzke C et al.. “Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm.” World journal of urology (2020). PMID: 32960328 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  283. [283]

    Jacobsen SJ, Girman CJ, Lieber MM. “Natural history of benign prostatic hyperplasia.” Urology (2001). PMID: 11750242 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  284. [284]

    Steers WD. “5alpha-reductase activity in the prostate.” Urology (2001). PMID: 11750244 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  285. [285]

    O'Leary MP. “Tamsulosin: current clinical experience.” Urology (2001). PMID: 11750250 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  286. [286]

    Kirby RS. “The natural history of benign prostatic hyperplasia: what have we learned in the last decade?” Urology (2000). PMID: 11074195 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  287. [287]

    Selman SH. “The McNeal prostate: a review.” Urology (2011). PMID: 21908026 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  288. [288]

    Kaplan SA. “5alpha-reductase inhibitors: what role should they play?” Urology (2001). PMID: 11750255 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  289. [289]

    Knutson T, Edlund C, Fall M et al.. “BPH with coexisting overactive bladder dysfunction--an everyday urological dilemma.” Neurourology and urodynamics (2001). PMID: 11385690 ↗

    L2OTHERCited in: History and Evolution of Treatment
  290. [290]

    Depaquit TL, Aguëro C, Uleri A et al.. “Persistence of nocturia after BPH surgery: a multicenter study.” World journal of urology (2025). PMID: 40540131 ↗

    L3OTHERCited in: History and Evolution of Treatment
  291. [291]

    Parsons JK, Dahm P, Köhler TS et al.. “Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020.” The Journal of urology (2020). PMID: 32698710 ↗

    L1GUIDELINECited in: Endoscopic & Procedural Technique Considerations
  292. [292]

    Thangasamy IA, Chalasani V, Bachmann A et al.. “Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012.” European urology (2012). PMID: 22575913 ↗

    L1SR_OBSCited in: Endoscopic & Procedural Technique Considerations
  293. [293]

    Sari Motlagh R, Mori K, Miura N et al.. “The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis.” BJU international (2020). PMID: 32564458 ↗

    L1SR_OBSCited in: Endoscopic & Procedural Technique Considerations
  294. [294]

    Biester K, Skipka G, Jahn R et al.. “Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non-inferiority).” BJU international (2011). PMID: 21883855 ↗

    L2SR_OBSCited in: Endoscopic & Procedural Technique Considerations
  295. [295]

    Bhatia S, Bhatia A, Richardson A et al.. “Prospective, non-randomized, controlled investigation of prostate (P) artery embolization (E) compared to holmium (Ho) laser enucleation of prostate for the treatment of symptomatic benign prostatic hyperplasia with prostate volume 80-250 cc: the hope trial outcome at 1 year.” World journal of urology (2026). PMID: 41528505 ↗

    L2RCTCited in: Endoscopic & Procedural Technique Considerations, Complications
  296. [296]

    Castellani D, Pirola GM, Pacchetti A et al.. “State of the Art of Thulium Laser Enucleation and Vapoenucleation of the Prostate: A Systematic Review.” Urology (2019). PMID: 31726185 ↗

    L2SR_OBSCited in: Endoscopic & Procedural Technique Considerations
  297. [297]

    Descazeaud A, Robert G, Azzousi AR et al.. “Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review.” BJU international (2009). PMID: 19154457 ↗

    L5REVIEW_NARRATIVECited in: Endoscopic & Procedural Technique Considerations, Special Populations & Pregnancy
  298. [298]

    Jung JH, Reddy B, McCutcheon KA et al.. “Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.” The Cochrane database of systematic reviews (2019). PMID: 31128077 ↗

    L1SR_OBSCited in: Endoscopic & Procedural Technique Considerations
  299. [299]

    Kutchukian S, Scilipoti P, Abi Abdallah M et al.. “Prostate morcellation devices: a systematic review and meta-analysis of clinical outcomes and efficiency.” BJU international (2026). PMID: 42420210 ↗

    L1SR_OBSCited in: Endoscopic & Procedural Technique Considerations
  300. [300]

    Sacco E, Gandi C, Li Marzi V et al.. “Extensive impact of COVID-19 pandemic on pelvic floor dysfunctions care: A nationwide interdisciplinary survey.” Neurourology and urodynamics (2021). PMID: 33492706 ↗

    L4OTHERCited in: Endoscopic & Procedural Technique Considerations
  301. [301]

    Kawai Y, Oka M, Kyotani J et al.. “Effect of the phytotherapeutic agent eviprostat on the bladder in a rat model of bladder overdistension/emptying.” Neurourology and urodynamics (2012). PMID: 23143863 ↗

    L5OTHERCited in: Endoscopic & Procedural Technique Considerations
  302. [302]

    Cho MC, Park JH, Jeong MS et al.. “Predictor of de novo urinary incontinence following holmium laser enucleation of the prostate.” Neurourology and urodynamics (2011). PMID: 21538499 ↗

    L2OTHERCited in: Endoscopic & Procedural Technique Considerations
  303. [303]

    Kuo TL, Teo JS, Foo KT. “The role of intravesical prostatic protrusion (IPP) in the evaluation and treatment of bladder outlet obstruction (BOO).” Neurourology and urodynamics (2015). PMID: 25727301 ↗

    L5OTHERCited in: Endoscopic & Procedural Technique Considerations
  304. [304]

    Taychert MT, Wells SA, Krieger JR et al.. “MRI-Derived Transition Zone Index Is Highly Predictive of Urodynamic Bladder Outlet Obstruction Prior to Holmium Laser Enucleation of the Prostate.” Neurourology and urodynamics (2025). PMID: 39801068 ↗

    L3OTHERCited in: Endoscopic & Procedural Technique Considerations
  305. [305]

    Huffman PJ, Yin E, Cohen AJ. “Evaluating Patient Preferences in Benign Prostatic Hyperplasia Treatment Using Conjoint Analysis.” Urology (2022). PMID: 35063462 ↗

    L2OTHERCited in: Endoscopic & Procedural Technique Considerations
  306. [306]

    Zhang TR, Thorogood SL, Sze C et al.. “Current Practice Patterns in the Surgical Management of Benign Prostatic Hyperplasia.” Urology (2023). PMID: 36863599 ↗

    L2OTHERCited in: Endoscopic & Procedural Technique Considerations
  307. [307]

    Vo AX, Ko OS, Hofer MD et al.. “Evaluation of Opioid Prescribing Patterns and Drivers of Variation Following Endoscopic Procedures for Benign Prostatic Hyperplasia Across an Integrated Academic Health System.” Urology (2021). PMID: 33482131 ↗

    L2OTHERCited in: Endoscopic & Procedural Technique Considerations
  308. [308]

    Dieudonne ZOJ, Nedjim SA, Kifle AT et al.. “Surgical Advances in Treating Benign Prostatic Hyperplasia in Africa: What About the Endoscopic Approach?” Urology (2024). PMID: 38653385 ↗

    L2OTHERCited in: Endoscopic & Procedural Technique Considerations
  309. [309]

    Weinstein IC, Wu X, Arenas-Gallo C et al.. “Adoption and Outcomes of Holmium Laser Enucleation of the Prostate in the United States.” Urology (2023). PMID: 37328009 ↗

    L2OTHERCited in: Endoscopic & Procedural Technique Considerations
  310. [310]

    Thomas JA, Tubaro A, Barber N et al.. “A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study.” European urology (2015). PMID: 26283011 ↗

    L1RCTCited in: Complications
  311. [311]

    Djaladat H, Mehrsai A, Saraji A et al.. “Suprapubic prostatectomy with a novel catheter.” The Journal of urology (2006). PMID: 16697808 ↗

    L2RCTCited in: Complications
  312. [312]

    Cartwright R, Mangera A, Tikkinen KA et al.. “Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men.” European urology (2014). PMID: 24491308 ↗

    L3SR_OBSCited in: Complications
  313. [313]

    Desai MM, Singh A, Abhishek S et al.. “Aquablation therapy for symptomatic benign prostatic hyperplasia: a single-centre experience in 47 patients.” BJU international (2018). PMID: 29319914 ↗

    L4TRIAL_NONRANDOMCited in: Complications
  314. [314]

    Desai M, Bidair M, Zorn KC et al.. “Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial.” BJU international (2019). PMID: 30734990 ↗

    L2TRIAL_NONRANDOMCited in: Complications
  315. [315]

    Pirola GM, Castellani D, Lim EJ et al.. “Urethral stricture following endoscopic prostate surgery: a systematic review and meta-analysis of prospective, randomized trials.” World journal of urology (2022). PMID: 35152322 ↗

    L1SR_OBSCited in: Complications
  316. [316]

    Suarez-Ibarrola R, Bach T, Hein S et al.. “Efficacy and safety of aquablation of the prostate for patients with symptomatic benign prostatic enlargement: a systematic review.” World journal of urology (2019). PMID: 31559476 ↗

    L4SR_OBSCited in: Complications
  317. [317]

    Gill BC, Miller LE, Bhattacharyya S et al.. “Complications of GreenLight Laser vs Transurethral Resection of the Prostate for Treatment of Lower Urinary Tract Symptoms: Meta-analysis of Randomized Trials.” Urology (2024). PMID: 38176618 ↗

    L1SR_OBSCited in: Complications
  318. [318]

    Titus RS, Su J, Riveros C et al.. “Comparative analysis of genitourinary toxicity following bladder outlet obstruction procedures in patients before versus after radiotherapy for localized prostate cancer: a retrospective cohort study using the TriNetX database.” Prostate cancer and prostatic diseases (2026). PMID: 42203958 ↗

    L2COHORTCited in: Complications
  319. [319]

    Dejene EF, Debele AA, Demilow TL. “Magnitude and outcome of urologic emergencies: prospective cohort study.” BMC emergency medicine (2026). PMID: 42092813 ↗

    L2COHORTCited in: Complications
  320. [320]

    Shekar A, Bagheri I, Sherman N et al.. “Transurethral Resection of the Prostate in Patients With Neurogenic Lower Urinary Tract Dysfunction.” Neurourology and urodynamics (2026). PMID: 41891497 ↗

    L5REVIEW_NARRATIVECited in: Complications
  321. [321]

    Anger JT, Goldman HB, Luo X et al.. “Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.” Neurourology and urodynamics (2017). PMID: 28455944 ↗

    L2OTHERCited in: Complications
  322. [322]

    Sandhu JS, Bixler BR, Dahm P et al.. “Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023.” The Journal of urology (2023). PMID: 37706750 ↗

    L1OTHERCited in: Prognosis & Natural History
  323. [323]

    Hernandez-Tirado A, Zheng R, Dadashian E et al.. “The effect of dutasteride on storage symptoms in men with lower urinary tract symptoms: a REDUCE trial analysis.” The aging male : the official journal of the International Society for the Study of the Aging Male (2026). PMID: 42011680 ↗

    L1RCTCited in: Prognosis & Natural History
  324. [324]

    Wang CJ, Lin YN, Huang SW et al.. “Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study.” The Journal of urology (2010). PMID: 21074790 ↗

    L1RCTCited in: Special Populations & Pregnancy
  325. [325]

    Ruszat R, Wyler S, Forster T et al.. “Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation.” European urology (2006). PMID: 16945475 ↗

    L2TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
  326. [326]

    Yoo S, Oh S, Park J et al.. “The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men.” BJU international (2018). PMID: 30125452 ↗

    L2COHORTCited in: Special Populations & Pregnancy
  327. [327]

    Zhang X, Zeng X, Dong L et al.. “The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome.” World journal of urology (2015). PMID: 25850975 ↗

    L1RCTCited in: Special Populations & Pregnancy
  328. [328]

    Ramachandran A, Chavannavar KM, Thiruvengadam G et al.. “Ejaculation preserving TURP (Ep-TURP): A viable alternative in sexually active males with BOO-a single centre prospective randomized study.” World journal of urology (2024). PMID: 39377798 ↗

    L1RCTCited in: Special Populations & Pregnancy
  329. [329]

    De Nunzio C, Kramer G, Marberger M et al.. “The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.” European urology (2011). PMID: 21497433 ↗

    L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
  330. [330]

    Gacci M, Eardley I, Giuliano F et al.. “Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.” European urology (2011). PMID: 21726934 ↗

    L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
  331. [331]

    Obayashi K, Saeki K, Kurumatani N. “Association between melatonin secretion and nocturia in elderly individuals: a cross-sectional study of the HEIJO-KYO cohort.” The Journal of urology (2013). PMID: 24384156 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  332. [332]

    Yu X, Elliott SP, Wilt TJ et al.. “Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies.” The Journal of urology (2008). PMID: 18499180 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  333. [333]

    Chung DE, Wysock JS, Lee RK et al.. “Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia.” The Journal of urology (2011). PMID: 21791350 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  334. [334]

    Schroeck FR, Hollingsworth JM, Kaufman SR et al.. “Population based trends in the surgical treatment of benign prostatic hyperplasia.” The Journal of urology (2012). PMID: 22999698 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  335. [335]

    Nik-Ahd F, Zhao S, Boscardin WJ et al.. “Development of the UroARC Surgical Calculator: A Novel Risk Calculator for Older Adults Undergoing Surgery for Bladder Outlet Obstruction.” The Journal of urology (2024). PMID: 38920141 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  336. [336]

    Fletcher SG, Clark SJ, Overstreet DL et al.. “An improved approach to followup care for the urological patient: drop-in group medical appointments.” The Journal of urology (2006). PMID: 16890706 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  337. [337]

    Fang CW, Liao CH, Wu SC et al.. “Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study.” World journal of urology (2018). PMID: 29427001 ↗

    L2COHORTCited in: Special Populations & Pregnancy
  338. [338]

    Lee SH, Chung BH, Kim CS et al.. “Survey on benign prostatic hyperplasia distribution and treatment patterns for men with lower urinary tract symptoms visiting urologists at general hospitals in Korea: a prospective, noncontrolled, observational cohort study.” Urology (2012). PMID: 22503769 ↗

    L2COHORTCited in: Special Populations & Pregnancy
  339. [339]

    Gourova LW, van de Beek C, Spigt MG et al.. “Predictive factors for nocturia in elderly men: a cross-sectional study in 21 general practices.” BJU international (2006). PMID: 16469020 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  340. [340]

    Pereira K, Halpern JA, McClure TD et al.. “Role of prostate artery embolization in the management of refractory haematuria of prostatic origin.” BJU international (2016). PMID: 27153766 ↗

    L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
  341. [341]

    Hong SK, Lee ST, Jeong SJ et al.. “Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.” BJU international (2009). PMID: 19874305 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  342. [342]

    Vaughan CP, Endeshaw Y, Nagamia Z et al.. “A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results.” BJU international (2009). PMID: 19220247 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  343. [343]

    Oelke M, Wagg A, Takita Y et al.. “Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.” BJU international (2017). PMID: 27988986 ↗

    L1OTHERCited in: Special Populations & Pregnancy
  344. [344]

    Novara G, Chapple CR, Montorsi F. “Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.” BJU international (2015). PMID: 25130493 ↗

    L1OTHERCited in: Special Populations & Pregnancy
  345. [345]

    Zhang Y, Liu M, Sun F et al.. “The efficacy of tranexamic acid in reducing intraoperative bleeding during transurethral resection of the prostate for benign prostatic hyperplasia (BPH): a systematic review and meta-analysis of randomized controlled trials.” PeerJ (2026). PMID: 41695713 ↗

    L1SR_MA_RCTCited in: Special Populations & Pregnancy
  346. [346]

    Xu H, Kuang W, Lin D et al.. “The efficacy and safety of 1470 nm diode laser in the treatment of benign prostatic hyperplasia: a prospective, multicenter study.” Lasers in medical science (2026). PMID: 41729325 ↗

    L1RCTCited in: Special Populations & Pregnancy
  347. [347]

    Berkowitz J, Carter HB, Gearhart JP. “Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes.” Urology (2008). PMID: 18308374 ↗

    L4CASE_REPORTCited in: Special Populations & Pregnancy
  348. [348]

    Gözen AS, Teber D, Moazin M et al.. “Laparoscopic transvesical urethrorectal fistula repair: a new technique.” Urology (2006). PMID: 16618569 ↗

    L4CASE_REPORTCited in: Special Populations & Pregnancy
  349. [349]

    Obayashi K, Saeki K, Kurumatani N. “Relationship between asymmetric dimethylarginine and nocturia in the general elderly population: The HEIJO-KYO cohort.” Neurourology and urodynamics (2014). PMID: 25066965 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  350. [350]

    Yoshikawa M, Torimoto K, Hirayama A et al.. “Daily salt intake is associated with leg edema and nocturnal urinary volume in elderly men.” Neurourology and urodynamics (2020). PMID: 32460398 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  351. [351]

    Kyoda Y, Saito Y, Kozen N et al.. “Impact of Prostatic Urethral Lift and Water Vapor Energy Therapy on Bladder Outlet Obstruction in Elderly or Comorbid Patients With Benign Prostatic Hyperplasia in Real-World Clinical Practice.” Neurourology and urodynamics (2025). PMID: 40990261 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  352. [352]

    Vesely S, Knutson T, Damber JE et al.. “TURP and low-energy TUMT treatment in men with LUTS suggestive of bladder outlet obstruction selected by means of pressure-flow studies: 8-year follow-up.” Neurourology and urodynamics (2006). PMID: 17016845 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  353. [353]

    Raizenne BL, Bouhadana D, Zorn KC et al.. “Functional and surgical outcomes of Aquablation in elderly men.” World journal of urology (2022). PMID: 36040501 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  354. [354]

    Liu H, Li B, Huang Y et al.. “Association between dynamic abdominal obesity (DAO) and benign prostatic hyperplasia (lower urinary tract symptoms): evidence from the China Health and Retirement Longitudinal Study (CHARLS).” World journal of urology (2026). PMID: 42347981 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  355. [355]

    Netsch C, Herrmann TRW, Bozzini G et al.. “Recent evidence for anatomic endoscopic enucleation of the prostate (AEEP) in patients with benign prostatic obstruction on antiplatelet or anticoagulant therapy.” World journal of urology (2021). PMID: 33721062 ↗

    L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
  356. [356]

    Wang P, Li J, Tang Z et al.. “Comprehensive efficacy of different prostate resection volumes for patients with benign prostatic hyperplasia: a systematic review and meta-analysis.” PeerJ (2026). PMID: 41727237 ↗

    L2SR_OBSCited in: Special Populations & Pregnancy
  357. [357]

    Li B, Zhang Z, Li J et al.. “The relationship between the a body shape index and benign prostatic hyperplasia in middle-aged and elderly adults: a nationwide cohort study.” BMC urology (2025). PMID: 41437019 ↗

    L2COHORTCited in: Special Populations & Pregnancy
  358. [358]

    Guo C, An L, Lu G et al.. “Acupuncture for benign prostatic hyperplasia in the elderly: A systematic review of acupoints.” Medicine (2025). PMID: 40797416 ↗

    L5SR_OBSCited in: Special Populations & Pregnancy
  359. [359]

    Campbell JA, Ali D, Rezaee ME et al.. “The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients with Prostate Cancer on Active Surveillance.” The Journal of urology (2026). PMID: 42341197 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  360. [360]

    Hutchison A, Farmer R, Chapple C et al.. “Characteristics of patients presenting with LUTS/BPH in six European countries.” European urology (2006). PMID: 16782265 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  361. [361]

    Dyson TE, Cantrell MA, Lund BC. “Lack of Association between 5α-Reductase Inhibitors and Depression.” The Journal of urology (2020). PMID: 32294395 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  362. [362]

    Ehdaie B, Vertosick E, Spaliviero M et al.. “The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance.” The Journal of urology (2013). PMID: 24018237 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  363. [363]

    Elshal AM, Elmansy HM, Elhilali MM. “Can we predict the outcome of 532 nm laser photoselective vaporization of the prostate? Time to event analysis.” The Journal of urology (2012). PMID: 22998906 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  364. [364]

    Paranhos M, Antunes A, Andrade E et al.. “The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.” BJU international (2009). PMID: 19426190 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  365. [365]

    Ulys A, Černiauskienė A, Geavlete P et al.. “Teverelix is a potential treatment option for the prevention of acute urinary retention recurrence in men suffering from benign prostatic hyperplasia.” International urology and nephrology (2024). PMID: 39428443 ↗

    L1RCTCited in: Prevention, Screening & Surveillance
  366. [366]

    Berges R, Höfner K, Gedamke M et al.. “Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).” World journal of urology (2014). PMID: 25135845 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  367. [367]

    Cui Y, Zhuo H. “Aging and prostate health: meta-analytic insights into age-related prostatic disorders.” Frontiers in oncology (2026). PMID: 42038379 ↗

    L2SR_OBSCited in: Prevention, Screening & Surveillance
  368. [368]

    Farzat M, Wagenlehner FM. “Incidental prostate cancer: is prostate-specific antigen density a valid predictor? A case-control study.” Therapeutic advances in urology (2025). PMID: 41190276 ↗

    L3CASE_CONTROLCited in: Prevention, Screening & Surveillance
  369. [369]

    Shelton PQ, Ivanowicz AN, Wakeman CM et al.. “Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.” Urology (2013). PMID: 23523297 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  370. [370]

    Pedrosa R, Lorigo J, Guerra AJ et al.. “Incidental prostate cancer following surgery for benign prostatic hyperplasia: a cohort study.” Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica (2026). PMID: 41705465 ↗

    L4COHORTCited in: Prevention, Screening & Surveillance
  371. [371]

    Matei E, Iorga IC, Deacu M et al.. “Dysregulated Cell Signaling Pathways in Prostate Tumoral Plasticity-Checkpoints.” Oncology research (2026). PMID: 42238015 ↗

    L5OTHERCited in: Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…